17th week of 2009 patent applcation highlights part 37 |
Patent application number | Title | Published |
20090104159 | Vascular/Lymphatic Endothelial Cells - The present invention provides methods to culture and use vascular endothelial cells, including lymphatic, venous and arterial endothelial cells. | 2009-04-23 |
20090104160 | Mobilization of Stem Cells After Trauma and Methods Therefor - Methods are presented in which release of stem cells from skeletal muscle is quantitated and correlated with severity of a disease or trauma, a future treatment option, prognosis, and/or anticipated time to recovery. Most preferably, the stem cell is a BLSC and/or an ELSC, and the stem cell isolation for the cell count is performed using sedimentation or filtration as principal separation step, thereby avoiding commonly used complicated, expensive, and time-consuming processes such as antibody-based separation and fluorescence-activated cell sorting. | 2009-04-23 |
20090104161 | METHOD FOR ACTIVATION TREATMENT OF ANTIGEN-PRESENTING CELL - Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or γδ T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs and/or γδ T cells induced using the activated antigen-presenting cell, immunocytes induced by the above-noted method, a medical composition comprising the immunocytes, and a treatment and prevention method using the immunocytes are provided. By co-pulsing antigen-presenting cells with bisphosphonate in addition to the pulse with a disease antigen, the ratio of disease antigen-specific CD8+ CTLs and/or γδ T cells and the number of the disease antigen-specific CD8+ CTLs and the γδ T cells can be increased, compared with the case where the co-pulse with bisphosphonate is not carried out. | 2009-04-23 |
20090104162 | Attenuated reoviruses for selection of cell populations - The present invention relates to methods for killing neoplastic cells, such as ras-activated cancerous cells, in vitro. In particular embodiments, an attenuated reovirus (e.g., a reovirus lacking a wild-type S1 gene) may be administered to a mixed cellular composition comprising cancerous cells and stem cells such as adult stem cells and/or hematopoietic stem cells; in these embodiments, the attenuated reovirus may result in killing of the cancerous cells with little or no damage to the healthy stem cells. | 2009-04-23 |
20090104163 | Immunomodulatory Properties of Multipotent Adult Progenitor Cells and Uses Thereof - Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described. | 2009-04-23 |
20090104164 | ANGIOGENIC CELLS FROM HUMAN PLACENTAL PERFUSATE - Provided herein are the production of vasculogenic or angiogenic cells from placental perfusate. Also provided are methods of treating an individual having a cardiac or vascular insufficiency, disease, disorder or condition comprising administering to said individual placental perfusate, placental perfusate cells, or combinations of placental perfusate or perfusate cells with placental or non-placental hematopoietic stem cells or adherent placental stem cells. | 2009-04-23 |
20090104165 | TRANSGENIC STRAINS OF TRICHODERMA AND THEIR USE IN BIOCONTROL - The present invention relates to a transgenic | 2009-04-23 |
20090104166 | STIMULATING NEURITE OUTGROWTH USING TCTEX-1-RELATED POLYPEPTIDES - A method of stimulating neurite outgrowth in a subject may include administering to the subject a formulation that includes a tctex-1-related polypeptide that stimulates neurite outgrowth in vitro. | 2009-04-23 |
20090104167 | Prophylactic/Ameliorating Agent for Menopausal Disorder and Functional Beverage/Food - Disclosed is a method for producing an estrogen-like active intermediate (e.g., secoisolariciresinol) by culturing a lignan (e.g., a lignan derived from | 2009-04-23 |
20090104168 | Use of Specific Lactic Bacteria for the Preparation of Immunomodulating Compositions - The invention concerns the use of two lactobacteria for the preparation of immunomodulating compositions, in particular for the treatment and/or prevention of allergies and immunodeficiencies, and specifically use of the following two strains | 2009-04-23 |
20090104169 | PET FOOD COMPOSITION FOR SKIN PHOTOPROTECTION - An ingestable composition for the photoprotection of the skin of pets which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one yeast and/or a carotenoid or derivative, included into an ingestable carrier. | 2009-04-23 |
20090104170 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS - The invention generally relates to a composition comprising an enriched NK cell population. The invention further relates to a method of treating a solid tumor or a hyperproliferative disorder by administering the enriched NK cell population to a mammalian subject in need thereof. | 2009-04-23 |
20090104171 | Metabolic Enhancement Therapy - A Metabolic Enhancement Therapy nutritional supplement for treating symptoms and conditions such as acute anxiety, hyperactivity, panic attacks, confusion, involuntary movements, sleep disorders, mood disorders, depression, anger, seizures, obsessive-compulsive behavior, unregulated fear, panic, neuronal disorders, autism, schizophrenia, attention deficit disorder (ADD), attention deficit hyperactive disorder (ADHD) and neuronally based immunologic disorders by administering to a mammal an effective amount of acetyl-L-carnitine, α-lipoic acid, biotin, vitamin B1, L-glutamine, Vitamin B6, taurine, folinic acid, vitamin B12, trimethylglycine, and L-tryptophan. | 2009-04-23 |
20090104172 | METHODS FOR KILLING SPORES AND DISINFECTING OR STERILIZING DEVICES - The present invention provides a method for killing or inactivating spores, by contacting the spores with a haloperoxidase, hydrogen peroxide, chloride or bromide ions, and ammonium ions. | 2009-04-23 |
20090104173 | NOVEL PROCESS FOR SOLUBILIZING PROTEIN FROM A PROTEINACEOUS MATERIAL AND COMPOSITIONS THEREOF - The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention. | 2009-04-23 |
20090104174 | Methods and compositions for reducing the appearance of dynamic facial wrinkles - The present invention relates to methods and compositions for reducing the appearance of dynamic facial wrinkles by administering oral and/or topical compositions comprising therapeutically-effective amounts of extracts of one or more relaxing herbal agents (“RHAs”) alone or in combination with one or more extracts of an edible solanaceous glycoalkaloid-containing plant (“ESGP”) or an edible glycoalkaloid-containing fungus (“EGF”) selected from plant species in the genus | 2009-04-23 |
20090104175 | USE OF CASPASES FOR THE PREPARATION OF MEDICAMENTS - The invention relates to caspases and to extracellular use of caspases for regulating cell functions. | 2009-04-23 |
20090104176 | COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS - One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided. | 2009-04-23 |
20090104177 | PEPTIDES FOR INHIBITING THE INTERACTION OF PROTEIN KINASE A AND PROTEIN KINASE A ANCHOR PROTEINS - The invention relates to a nucleic acid sequence encoding peptides which inhibit the interaction of protein kinase A (PKA) and protein kinase A anchor proteins (AKAP), to a host organism comprising said nucleic acid sequence and optionally expressing said peptides, to the use of said peptides and of said host organism in investigating diseases associated with said AKAP-PKA interaction, and to the use of said peptides as pharmaceutical agent for the treatment of such diseases. | 2009-04-23 |
20090104178 | Chemokine binding activity of viral tnf receptors and related proteins - Chemokine binding activity of viral TNF receptors and related proteins. The invention relates to a C-terminal domain (CTD) of viral tumour necrosis factor receptors (vTNFRs) CrmB or CrmD or CTD homologues (CTD1, CTD2 and CTD3) from poxvirus and their functional homologues, including derivatives, and fragments, for use in binding chemokines and their analogues and/or to enhance the immunomodulatory properties of TNFRs or in bloking binding of chemokines to their corresponding cell surface receptors and/or to modulate chemokine biological activity. | 2009-04-23 |
20090104179 | Ionizing-radiation-responsive compositions, methods, and systems - A method, composition and system respond to ionizing radiation to adjust biological activity. In some approaches the ionizing radiation is X-ray or extreme ultraviolet radiation that produces luminescent responses that induce biologically active responses. | 2009-04-23 |
20090104180 | NOVEL P-SELECTIN LIGAND PROTEIN - A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed. | 2009-04-23 |
20090104181 | Antibodies for Discrimination of Prions - In the present invention, we described the use of anti-DNA antibody for the detection of prions and diagnosis of Transmissible Spongiform Encephalopathies (TSE) diseases in animals and humans. | 2009-04-23 |
20090104182 | INHIBITION OF TRISTETRAPROLINE FOR PROTECTION OF THE HEART FROM CARDIAC INJURIES - The present invention relates to compounds suitable for the treatment of conditions which may be improved, at least in part, by increasing TNF α production. The invention further relates to assays for the identification of an individual at increased risk for or suffering front such conditions and to methods of screening compounds for their ability to enhance TNF α biosynthesis. | 2009-04-23 |
20090104183 | GLUE COMPOSITION FOR LUNG VOLUME REDUCTION - The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema. | 2009-04-23 |
20090104184 | Pharmaceutical compositions containing monoclonal anti idiotypic anti-CA-125 antibody and aluminium - The present invention refers to a pharmaceutical composition for parenteral administration as vaccine comprising a monoclonal antibody and as adjuvant an aluminium derivative. | 2009-04-23 |
20090104185 | Methods and Compositions for Mycoplasma Toxins - The present invention provides | 2009-04-23 |
20090104186 | Melanoma-associated MHC class I associated oligopeptides and the uses thereof - The present invention relates to certain melanoma-associated oligopeptides that are recognized by CD8-positive cytotoxic T-lymphocytes (CTLs) as peptide antigen and which elicit a CTL-induced lysis and/or apoptosis of tumor cells. The present invention also relates to the use of these melanoma-associated oligopeptides in cancer therapy. | 2009-04-23 |
20090104187 | Novel Rabbit Antibody Humanization Methods and Humanized Rabbit Antibodies - The present invention is directed to novel and improved methods for humanizing rabbit heavy and light variable regions. The resulting humanized rabbit heavy and light chains and antibodies and antibody fragments containing are well suited for use in immunotherapy and immunodiagnosis as they retain the antigen binding affinity of the parent antibody and based on their very high level of sequence identity to human antibody sequences should be essentially non-immunogenic in humans. The invention exemplifies the protocol for the manufacture of therapeutic humanized anti-human TNF-alpha and anti-human IL-6 antibodies. | 2009-04-23 |
20090104188 | ANTI-HEPATITIS C VIRUS ANTIBODY AND USES THEREOF - Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable of neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation. | 2009-04-23 |
20090104189 | NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT - The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention. | 2009-04-23 |
20090104190 | HUMANIZED ANTI-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES - A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions. | 2009-04-23 |
20090104191 | Prevention of tumors with monoclonal antibodies against neu - Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface in an individual at high risk of developing tumors are disclosed. | 2009-04-23 |
20090104192 | Monoclonal Antibodies to Hepatocyte Growth Factor - The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. | 2009-04-23 |
20090104193 | SEMA4D in Cancer Diagnosis, Detection and Treatment - This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the SEM A4D gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the SEMA4D gene. | 2009-04-23 |
20090104194 | BI-DIRECTIONAL ANTIBODY FOR TREATMENT OF OCULAR DISORDERS - A system and method for treating ocular disorders are disclosed. Specifically, the system and method administer bi-directional antibodies to treat a retina. Structurally, each bi-directional antibody has a first receptor arm and a second receptor arm. Further, each first receptor arm possesses binding affinity for retinal cells and each second receptor arm possesses binding affinity for melanin. After the antibodies are administered to the retina, the first receptor arms attach to the retinal cells. Thereafter, melanin is delivered to the retina and the second receptor arms are fixed to the melanin. In this manner, melanin is concentrated at the retinal cells. | 2009-04-23 |
20090104195 | TARGETED LIGANDS - The invention contemplates a composition containing a multispecific ligand containing at least a first ligand binding moiety and a second ligand binding moiety. The first ligand binding moiety specifically binds with a pre-selected first affinity to at least a first ligand. The first ligand has a first biodistribution. The second ligand binding moiety specifically binds with a pre-selected affinity to at least a second ligand. The second ligand has a second biodistribution. The affinity of first and second ligand binding moieties are selected to bias the biodistribution of the multispecific ligand in favor of a selected location of one or both of the ligands. | 2009-04-23 |
20090104196 | Antibodies For Use in Identifying and/or Scoring Prostate Cancer and Androgen Receptor-Dependent Gene Expression Control - The invention relates to antibodies for use for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical and diagnostical compositions comprising such antibodies. The invention also relates to a method for identifying and/or scoring prostate carcinomas. Furthermore, the invention relates to the use of at least one siRNA (“short interfering RNA”) and/or at least one anti-LSD1 antibody for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal or for the manufacture of a medicament for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to a pharmaceutical composition for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one siRNA and/or at least one anti-LSD1 antibody suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to a method for controlling the androgen receptor-dependent gene expression in a mammal, said process comprising the step of administering to said mammal, on a suitable route, an effective dose of a pharmaceutical composition modulating an activity of the lysine-specific demethylase (LSD1) in a mammal. | 2009-04-23 |
20090104197 | vWFA and/or ANT_IG Domain Containing Proteins - This invention relates to novel proteins (herein termed INSP141, INSP142, INSP143, and INSP144), herein identified as anthrax receptor-like proteins containing von Willebrand factor A (vWFA) and Anthrax receptor extracellular (ANT_IG) domains and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease. | 2009-04-23 |
20090104198 | VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) PROTEIN AND GENE, MUTANTS THEREOF, AND USES THEREOF - Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. | 2009-04-23 |
20090104199 | Breast Cancer Resistance Protein (BCRP) And The DNA Which Encodes It - The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs. | 2009-04-23 |
20090104200 | MODULATING INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE CENTRAL NERVOUS SYSTEM - Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., ASC, NALP1) in a mammalian inflammasome (e.g., the NALP1 inflammasome) and have use as treatments for SCI, TBI, stroke, and autoimmune and CNS diseases in a mammal. In a rodent model of SCI, therapeutic neutralization of ASC using a polyclonal antibody that specifically binds to ASC inhibited the inflammasome, reduced caspase-1 activation, XIAP cleavage, and interleukin processing, resulting in significant tissue sparing and functional improvement. Additionally, in a rodent model of TBI, neutralization of ASC after TBI reduced caspase-1 activation and XIAP cleavage. Further, in a rodent thromboembolic stroke model, neutralization of NLRP1 resulted in reduced histopathological damage in mice and reduced cytokine activation, suggesting that the inflammasome complex forms in the brain after stroke and is a therapeutic target for reducing the detrimental consequences of post-stroke inflammation. | 2009-04-23 |
20090104201 | METHODS AND COMPOSITIONS FOR TREATMENT AND DIAGNOSIS OF FIBROSIS, TUMOR INVASION, ANGIOGENESIS, AND METASTASIS - The present disclosure provides innovative methodology and related compositions and kits for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX and an inhibitor of a LOXL, or a synergistic combination of an inhibitor of LOX or LOXL combined with other therapeutic agents. Also provided are innovative methods for selecting agents that prevent or inhibit tumor invasion, angiogenesis and metastasis, by contacting cells that are in an epithelial-mesenchymal transition (EMT) state with a candidate agent and detecting a change in the EMT state of the cells. Methods and related compositions and kits for diagnosing or monitoring various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using molecules or agents that specifically recognize processed forms of LOX or LOXL are also provided. Also provided herein are methods and related compositions, medical devices, systems and kits for preventing or treating various diseases and conditions associated with fibrosis with compositions comprising inhibitors of LOX or LOXL. Such diseases or conditions include pathological cardiovascular conditions and diseases such as hypertension, hypertensive heart disease, myocardial infarction, atherosclerosis, and restenosis, liver fibrosis, kidney fibrosis, lung fibrosis, dermal scaring, keloid formation, and Alzheimer's disease. | 2009-04-23 |
20090104202 | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases - An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain capable of specifically binding a CD44 polypeptide as set forth in SEQ ID NO: 2 and incapable of binding a CD44 polypeptide selected from the group consisting of: SEQ ID NO: 4 or 6. | 2009-04-23 |
20090104203 | Compositions and Methods for Regulating Osteoclast Differentiation, Activation and Bone Resorption - Provided is a purified, negative regulator of osteoclast differentiation and bone resorption, specifically LRRc17. Further provided are methods and compositions for treating degenerative bone disorders, and treatments and prophylactic approaches for regulating bone resorption, and for decreasing or inhibiting the excessive bone loss associated with abnormal or excessive generation of or activity of osteoclasts. | 2009-04-23 |
20090104204 | Human Binding Molecules Having Killing Activity Against Staphylococci and Uses Thereof - The present invention provides human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from | 2009-04-23 |
20090104205 | Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus - This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial virus which is MAb1129 and the use thereof for the prevention and/or treatment of RSV infection. | 2009-04-23 |
20090104206 | Bone microenvironment modulated migraine treatments - Novel etiology and pathogenesis of premenstrual headache and premenstrual migraine are presented and novel treatment methods are provided. Present invention identifies how declining estrogen results in a transient elevation in extracellular calcium concentrations via osteoclast upregulation. The elevated extracellular calcium pathogenesis is then traced, from bone to brain, and includes depolarization of nerves, hyperactive neurotransmitter release, and hyperactive muscle contractility. Treatment methods are provided that target the earliest steps of the underlying etiology, in order to provide the most efficacious treatment possible. The treatment methods presented include use of compounds such as calcitonin and SERMs such as raloxifene. | 2009-04-23 |
20090104207 | Hepatitis C Virus Neutralizing Antibodies - The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies. | 2009-04-23 |
20090104208 | House Dust Mite Allergen - A polypeptide comprising an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or comprising at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1. | 2009-04-23 |
20090104209 | METHODS OF REDUCING A VIRAL INFECTION AND KITS THEREFORE - A method for treating and/or preventing a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9)-susceptible viral infection comprising increasing a PCSK9 activity and/or expression in a biological system infected by the virus, whereby the increased PCSK9 activity and/or expression treats and/or prevents the viral infection in the biological system. Methods of classifying subjects, methods of screening and kits therefore. | 2009-04-23 |
20090104210 | Peptide compounds for treating obesity and insulin resistance - Compounds comprising an angiopoietin-like protein 6 (Angptl6) peptide for use in the treatment of metabolic syndrome, in particular, obesity and insulin resistance are described. | 2009-04-23 |
20090104211 | Treatment of atherosclerosis - The invention relates to a method and a device for commissioning articles from a first number of pick-up sections ( | 2009-04-23 |
20090104212 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS USING TWO-PHOTON SIMULTANEOUS ABSORPTION - A method for treating a cell proliferation disorder in a subject, comprising:
| 2009-04-23 |
20090104213 | Vaccine for House Dust Mite Allergen Using Naked DNA - Vaccination with the DNA encoding T-cell epitopes to the house dust mite | 2009-04-23 |
20090104214 | Synthetic peptides containing the motif "YWWLXP" as anthrax toxin antidotes - Specific inhibitors, in Multiple Antigen Peptide form, which inhibit the interaction between protective antigen and lethal factor and neutralize anthrax toxin in vivo. Anti protective antigen peptides were selected from a phage library by competitive panning with lethal factor. Selected 12mer peptides were synthesized in tetra-branched form and systematically modified to achieve peptides with higher affinity and inhibitory efficiency. | 2009-04-23 |
20090104215 | Methods and compositions for modulating tumor cell activity - Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding to clusterin. | 2009-04-23 |
20090104216 | Peptide-Based Influenza Vaccine Formulation - Peptide-based anti-influenza formulations against influenza A and B are disclosed. The peptides are derived from influenza-based epitopes. The formulations are based on peptide mixtures which may be formulated so that variability is present at particular residues. The formulations can be used to prepare vaccines for preventing influenza in human, avian, murine or equine animals. | 2009-04-23 |
20090104217 | Pharmaceutical Composition Comprising An Antigen - The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected from neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer. | 2009-04-23 |
20090104218 | Group B Streptococcus - Polypeptides and nucleic acids from | 2009-04-23 |
20090104219 | Antigenic polypeptide SE36 of malaria plasmodium, process for purification thereof, and vaccine and diagnostic agent using the antigen - The present invention provides a polypeptide SE36 derived from the N-terminal domain (47 kd) of SERA (serine-repeat antigen) produced by malaria parasite, | 2009-04-23 |
20090104220 | Method to Make a Peptide-Carrier Conjugate with a High Immunogenicity - The present invention provides a method for making a peptide-carrier conjugate. The method comprises modifying a first peptide to produce a second peptide so that the pI of the second peptide is in a favorable range or closer to the range than the pI of the first peptide, and conjugating a plurality of the second peptide to OMPC to obtain a peptide-carrier conjugate. The peptide load, or the solubility of the conjugate, or both of them are increased by the modification. | 2009-04-23 |
20090104221 | RAPID GENERATION OF T CELL-INDEPENDENT ANTIBODY RESPONSES TO T CELL-DEPENDENT ANTIGENS - The present invention comprises the use of follicular dendritic cells (FDCs) or FDC-like cells to generate FDC-dependent, but T cell-independent, B cell responses to T cell-dependent antigens, with antigen-specific and polyclonal antibody production in ˜48 h. In another embodiment, a germinal center (GC) lymphoid tissue equivalent (LTE) was used to generate antigen-specific IgM, followed by switching to IgG. The GC LTE model can be used in vaccine assessment. Dual forms of immunogen were used in the GC LTE and in vivo. Dual immunogens resulted in rapid, specific IgM responses and enhanced IgG responses. This vaccine design approach can be used, for example, to provide rapid IgM protection (˜24-48 h) and high-affinity IgG more quickly in people moving to areas with endemic disease, or in people with T cell insufficiencies, who can be immunized to rapidly generate protective IgM. | 2009-04-23 |
20090104222 | COMPOSITION COMPRISING A GLUCAN OR A GLUCAN DERIVATIVE AND A PESTICIDE AND METHODS FOR IMPROVING PLANT HEALTH - The present invention relates to a method for improving the health of an agricultural plant by applying to the plant, the locus where the plant is growing or is expected to grow, and/or the seeds from which the plant grows a non-phytotoxic effective amount of active ingredient mixtures, comprising component (A) and component (B) wherein component (A) is a glucan or a glucan derivative or a seaweed extract and component (B) is as defined in the present specification. | 2009-04-23 |
20090104223 | Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations - The invention relates to a method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens can be introduced, wherein synergism between said components is found with respect to the immunogenicity of the response obtained. The preparation may also contain stabilizers and preservatives. The resulting antigenic structures can be used in the pharmaceutical industry as preventive or therapeutic vaccine formulation both for human and veterinary use and as part of diagnostic system. | 2009-04-23 |
20090104224 | MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES - The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. | 2009-04-23 |
20090104225 | USE OF MVA TO TREAT PROSTATE CANCER - The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane. | 2009-04-23 |
20090104226 | Alphavirus Vectors for Respiratory Pathogen Vaccines - Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions. | 2009-04-23 |
20090104227 | VACCINE COMPOSITION FOR THE PREVENTION OF CMV INFECTION - The invention relates to a method for preventing HCMV infection in HCMV seronegative human subjects and for preventing HCMV congenital infection in newborns, which method comprises administering an effective amount of a vaccine composition containing the gB antigen of HCMV in an O/W emulsion to the seronegative human subjects. | 2009-04-23 |
20090104228 | Influenza Virus Vaccine - The invention relates to influenza virus vaccines, and in particular to a reassortant influenza virus which has at least its hemagglutinin gene derived from a non-pathogenic or low pathogenic influenza virus, and its other genes derived from a donor strain. In one embodiment the influenza virus is a 7:1 reassortant, in which only the hemagglutinin gene is derived from a non-pathogenic influenza virus. The virus is useful for production of vaccines against influenza, including influenza caused by highly pathogenic influenza virus strains. | 2009-04-23 |
20090104229 | NOVEL USE - The invention provides the use of a) an HIV Tat protein or polynucleotide; or b) an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or polynucleotide (Nef-Tat); and an HIV gp120 protein or polynucleotide in the manufacture of a vaccine for the prophylactic or therapeutic immunisation of humans against HIV. | 2009-04-23 |
20090104230 | COMPOSITIONS AND METHODS OF USING CAPSID PROTEIN FROM FLAVIVIRUSES AND PESTIVIRUSES - This invention provides methods of inducing cell death with Flavivirus or Pestivirus capsid protein, such as West Nile virus (WNV) capsid protein, and functional fragments thereof. The invention also provides methods of treating patients suffering from diseases characterized by hyperproliferating cells by administering pharmaceutical compositions comprising WNV or other virus including Flavivirus or Pestivirus capsid or other protein or a nucleic acid molecule encoding the same. Methods of identifying compounds which have anti-viral and/or anti-WNV and/or anti-Flavivirus and/or anti-Pestivirus capsid or other protein activity are disclosed. The invention also provides vaccine compositions comprising capsid or other proteins, or fragments thereof, or nucleic acids encoding same, from WNV or other virus including Flavivirus or Pestivirus and a pharmaceutically acceptable carrier. The invention also provides diagnostic methods and kits for identifying individuals exposed to WNV or other viruses including Flavivirus or Pestivirus. | 2009-04-23 |
20090104231 | VACCINE - The present invention relates to methods and compositions useful in the treatment and prevention of Hepatitis C virus (HCV) infections and the symptoms and diseases associated therewith. In particular the present invention relates to DNA vaccines comprising polynucleotide sequences encoding HCV proteins, and methods of treatment of individuals infected with HCV comprising administration of the vaccines of the present invention. | 2009-04-23 |
20090104232 | COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST YERSINIA PESTIS - The invention provides a gene transfer vector for inducing an immune response against | 2009-04-23 |
20090104233 | IDENTIFICATION OF RESIDUES CRITICAL FOR THE FUNCTION OF THE VIBRIO CHOLERAE VIRULENCE REGULATOR ToxT BY SCANNING ALANINE MUTAGENESIS - Disclosed are | 2009-04-23 |
20090104234 | METHODS OF TREATING CHRONIC NEUROGENIC INFLAMMATION USING MODIFIED CLOSTRIDIAL TOXINS - The present specification discloses modified Clostridial toxins, compositions comprising such toxins and methods of treating chronic neurogenic inflammation in a mammal using such modified Clostridial toxins and compositions. | 2009-04-23 |
20090104235 | Method for Producing of a Preparation of a Solid Dmso-Containing Silicone Oil Emulsion for the Binding of Reactive Oxygen Compounds in Human and Animal Bodies - The invention relates to a method for production of an oral, rectal or vaginal preparation comprising a solid silicone oil emulsion, characterized in that said preparation comprises 0.01-85 wt. % dimethicone and 0.01-45 wt. % dimethylsulphoxide, whereby the preparation dissolves after application and the emulsion is released. The dimethylsulphoxide is then resorbed and the remaining components of the preparation remain in the gut or vagina as a result of the molecular size thereof and subsequently are totally deposited. The invention further relates to a preparation and a method for production of a preparation made from a silicone oil emulsion. | 2009-04-23 |
20090104236 | PHARMACEUTICAL SOLID HYBRIDS - The invention provides solid pharmaceutical hybrids that are useful in the treatment or diagnosis of diseases, as well as methods of producing the solid pharmaceutical hybrids. | 2009-04-23 |
20090104237 | METHOD FOR INCREASING TISSUE OXYGENATION - Disclosed are methods and compositions for increasing tissue oxygen levels by administration of superoxygenated compositions of tissue surfaces. The methods are applicable to treatment of a wide variety of conditions including burns, bedsores, ulcers, necrosis and anaerobic infections. | 2009-04-23 |
20090104238 | METHOD FOR PRODUCING POLYMERS MODIFIED BY SILICONE - Silicone-modified polymers of ethylenically unsaturated monomers are prepared in the form of aqueous polymer dispersions or water-redispersible polymer powders, by
| 2009-04-23 |
20090104239 | Method, Material and System for Controlled Release of Anti-Microbial Agents - There is provided a method for treating a fluid with an anti-microbial agent comprising the steps of: (a) contacting the fluid with a solid material containing an anti-microbial agent; and, (b) abrading an interface of the solid material and removing particles therefrom and exposing an underlying surface of the solid material to the fluid, thereby facilitating release of the antimicrobial agent of the underlying surface of the solid material and/or the removed particles into the fluid. The solid material comprises an anti-microbial agent dispersed and/or embedded in a solid carrier. Typically, the anti-microbial agent is one or more of a metal, metal oxide, metal compound, metal salt, metal-ligand complex or derivatives thereof based on silver, copper and zinc. | 2009-04-23 |
20090104240 | Dual Drug Formulations For Implantable Medical Devices For Treatment of Vascular Diseases - The present invention relates to implantable medical devices coated with the polymer containing at least an olimus and a corticosteroid for the treatment of vascular diseases. | 2009-04-23 |
20090104241 | RANDOM AMORPHOUS TERPOLYMER CONTAINING LACTIDE AND GLYCOLIDE - The present invention provides an amorphous terpolymer for a coating on an implantable device for controlling release of drug and methods of making and using the same | 2009-04-23 |
20090104242 | NIOBIUM OXIDE COMPOSITIONS, NANOSTRUCTURES, BIOACTIVE FORMS AND USES THEREOF - Self-organized niobium oxide nanocones with nano-sized tips are prepared by anodization of niobium in the presence of an electrolyte such as hydrofluoric acid (HF) (aq.). Dimensions and integrity of the bulk nanostructures formed are strongly dependent on potential, temperature, electrolyte composition, and anodization times. Accordingly, the morphology, topology, uniformity and bioactivity of the niobium oxide nanostructures formed can be readily adjusted by adjusting these anodization parameters. A bioactive form of crystalline niobium oxide is formed by anodizing niobium metal in the presence of an electrolyte that includes HF and at least one salt such as Na | 2009-04-23 |
20090104243 | Drug cores for sustained release of therapeutic agents - A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues. | 2009-04-23 |
20090104244 | THERAPEUTIC AGENT-ELUTING MEDICAL DEVICES HAVING TEXTURED POLYMERIC SURFACES - A medical device comprising: (a) a substrate having first and second surfaces, (b) a therapeutic-agent-eluting polymeric layer disposed over the first substrate surface and (c) a textured polymeric layer that is textured to promote cell attachment, cell growth, or both, disposed over the second surface. | 2009-04-23 |
20090104245 | BIODEGRADABLE CARRIER AND METHOD FOR PREPARATION THEREOF - A biodegradable carrier is produced for preservation and/or controlled delivery of biologically active agents where said biodegradable carrier is a silica xerogel which is made from water and silane by using acid or base as a catalyst, and biologically active agents in said biodegradable carrier are infecting and/or transfecting viruses. Silica xerogel material can be pharmaceutically acceptable and it can be used as a medicine. | 2009-04-23 |
20090104246 | LOCAL ADMINISTRATION OF A COMBINATION OF RAPAMYCIN AND PANZEM FOR THE TREATMENT OF VULNERABLE PLAQUE - Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices. | 2009-04-23 |
20090104247 | Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings - Provided herein are coating designs for the tailored release of two therapeutic agents from polymer coatings and methods of making and using the same. | 2009-04-23 |
20090104248 | Lacrimal implants and related methods - Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed. | 2009-04-23 |
20090104249 | Exotoxin Inhibitory Factor - The invention provides an exotoxin inhibitory factor, compositions containing the factor, methods of using the compositions. | 2009-04-23 |
20090104250 | Medical or veterinary digestive tract utilization systems and methods - Systems and methods are described for implementing or deploying medical or veterinary utility modules (a) operable for mooring at least partly within a digestive tract, (b) small enough to pass through the tract per vias naturales and including a wireless-control component, (c) having one or more attachment protrusions positionable adjacent to a mucous membrane, (d) configured to facilitate redundant modes of attachment, (e) facilitating a “primary” material supply deployable within a stomach for an extended and/or controllable period, (f) moored by one or more adaptable extender modules supported by a subject's head or neck, and/or (g) configured to facilitate supporting at least a sensor within a subject's body lumen for up to a day or more. | 2009-04-23 |
20090104251 | HEAT STABLE MICROCAPSULES AND METHODS FOR MAKING AND USING THE SAME - A method of manufacturing a microcapsule that may include complex coacervating a protein and a polyanionic polymer to form a coacervate, the coacervate being at least a portion of the microcapsule, and wherein a cross-linking reagent is not used during the coacervation. | 2009-04-23 |
20090104252 | WOUND DRESSING FOR IMPROVING SCARRING - An occlusive wound dressing for application to wound sites to accelerate the healing process and improve the appearance of the final mature scar including a silicone gel sheet and antimicrobial silver disposed in the silicone gel sheet where the silver may be present in the form of particles or wires and the particles or wires may be disposed in the silicone gel sheet in a grid pattern or as a lattice, and an adhesive may be present on at least one face of the silicone gel sheet. The adhesive may be present in the form of spaced lines with adhesive-free areas between the lines containing the antimicrobial silver. It is preferred that an antibruising agent is also included in the silicone gel. | 2009-04-23 |
20090104253 | Hemostatic biocidal dressing - A hemostatic biocidal dressing includes pro-coagulant and biocidal agents providing a physical barrier to bleeding as well as chemical action to promote blood coagulation and thereby arrest coverage. At the same time, biocidal properties of the dressing prevent the introduction of infected agents and the establishment of infection within wounded tissue. A silverized textile provides biocidal action while a granulated hemostatic agent disposed within interstitial regions between polymer fibers provides coagulating action. | 2009-04-23 |
20090104254 | Controlled Release Hydrogels - Formulations and methods for their preparation including a hydrogel including a crosslinked matrix comprising a polymer, and a one or more liposomes containing a therapeutic agent. | 2009-04-23 |
20090104255 | Liposome Drug Delivery of Polycyclic, Aromatic, Antioxidant or Anti-Inflammatory Compounds - This invention comprises pharmaceutical compositions for administering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver polycyclic, aromatic, antioxidant or anti-inflammatory compounds to the gastrointestinal tract after oral administration. | 2009-04-23 |
20090104256 | Methods of Treating Pulmonary Disorders with Liposomal Amikacin Formulations - Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period. | 2009-04-23 |
20090104257 | Liposomal Vancomycin Formulations - The present disclosure relates in part to liposomal vancomycin compositions having low lipid to drug ratios and high concentration of vancomycin. The present disclosure also relates in part to methods of making such compositions. | 2009-04-23 |
20090104258 | Use of tocopheryl phosphate as an agent for preventing or slowing down the appearance of the effects of skin ageing - The invention relates to a cosmetic composition of a tocopheryl phosphate, especially in its dl or d form, or in the form of a cosmetically acceptable salt or ester thereof, as a cosmetic agent for preventing or slowing down the appearance of the effects of skin ageing, in particular of photoageing of the skin, said tocopheryl phosphate being at least partially encapsulated in lipid vesicles, in particular liposomes. It relates most particularly to the use of alpha-tocopheryl phosphate. It also relates to cosmetic compositions containing a tocopheryl phosphate, in particular an alpha-tocopheryl phosphate, at least partially incorporated into lipid vesicles, in particular liposomes, these compositions being in particular in the form of a serum or of a stable emulsion. The invention also relates to a cosmetic skincare process. | 2009-04-23 |